1f1b77a0-a237-47d7-b672-320c327517a3
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 61
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.410
- INTERFERON_GAMMA_RESPONSE+0.330
- ALLOGRAFT_REJECTION+0.240
- MITOTIC_SPINDLE+0.220
- SPERMATOGENESIS+0.150
- HEME_METABOLISM+0.100
- KRAS_SIGNALING_DN+0.090
- TNFA_SIGNALING_VIA_NFKB+0.090
- CHOLESTEROL_HOMEOSTASIS+0.020
- G2M_CHECKPOINT+0.020
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.650
- OXIDATIVE_PHOSPHORYLATION-0.540
- ANGIOGENESIS-0.500
- MYC_TARGETS_V1-0.480
- MYC_TARGETS_V2-0.440
- HEDGEHOG_SIGNALING-0.430
- ADIPOGENESIS-0.380
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.370
- MTORC1_SIGNALING-0.360
- UNFOLDED_PROTEIN_RESPONSE-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR10900583 | — | — | 0.818 |
| 2 | AUR-AG0J-TTP1-A-1-0-R-A741-41 | — | D | 0.818 |
| 3 | ERR2208899 | — | — | 0.817 |
| 4 | TCGA-P3-A5QE-01A-11R-A28V-07 | — | — | 0.809 |
| 5 | TCGA-MN-A4N5-01A-11R-A24X-07 | — | cohortA1 | 0.803 |
| 6 | TCGA-DK-A3IV-01A-22R-A21D-07 | — | — | 0.801 |
| 7 | AUR-AF9A-TTP1-A-1-0-R-A741-41 | — | D | 0.800 |
| 8 | TCGA-ZF-A9R7-01A-11R-A38B-07 | — | — | 0.799 |
| 9 | TCGA-EW-A1J5-01A-11R-A13Q-07 | — | B | 0.788 |
| 10 | X65f5effa.07f7.4ed3.9e0a.3a0d9d451474 | — | cohortA1 | 0.788 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.410 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.330 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.240 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.220 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.150 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.100 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.090 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.090 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.020 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.020 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.010 | Idelalisib | — uncovered |